Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom

Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom

Abstract Background Characteristics of patients using newer 2nd and 3rd line antidiabetic drugs in a real-world setting are poorly understood. We described the characteristics of new users of sodium-glucose co-transporter-2 inhibitors (SGLT-2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and glucag...

Full description

Bibliographic Details
Main Authors: Vanessa C. Brunetti, Audray St-Jean, Sophie Dell’Aniello, Anat Fisher, Oriana H. Y. Yu, Shawn C. Bugden, Jean-Marc Daigle, Nianping Hu, Silvia Alessi-Severini, Baiju R. Shah, Paul E. Ronksley, Lisa M. Lix, Pierre Ernst, Kristian B. Filion, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Endocrine Disorders
Subjects:
Type 2 diabetes
sodium-glucose co-transporter 2 inhibitors
glucagon-like peptide 1 receptor agonists
dipeptidyl peptidase 4 inhibitors
Online Access:https://doi.org/10.1186/s12902-022-01140-1

Internet

https://doi.org/10.1186/s12902-022-01140-1

Similar Items